Beste apotheek van Nederland

Hatch J P. Psychophysiological aspects of sexual dysfunction.
[Review] [88 refs]. Arch Sex Behav 1981;10(1):49-64.
Hatzichristou D G, Pescatori E S. Current treatments and
emerging therapeutic approaches in male erectile dysfunction.
BJU International - Supplement 2001;88(3):11-17.
Hatzimouratidis K, Hatzichristou D G. Treatment options for
erectile dysfunction in patients failing oral drug therapy. Eau
Update Series 2004;2(2):75-83.
Hayes A, Kochar M S. Erectile dysfunction in patients with
hypertension: Management tactics. Consultant
2004;44(12):1534-1540.
Heaton J P. Apomorphine: an update of clinical trial results. Int
J Impot Res 2000;12Suppl-73.
Heaton J P W. Characterising the benefit of apomorphine SL
(Uprima) as an optimised treatment for representative
populations with erectile dysfunction. Int J Impot Res
2001;13(SUPPL. 3):S35-S39.
Hedelin H, Stroberg P. Treatment for erectile dysfunction based
on patient-reported outcomes: To every man the PDE5 inhibitor
that he finds superior. Drugs 2005;65(16):2245-2251.
Hedlund H, Hedlund P. Pharmacotherapy in erectile dysfunction
agents for self-injection programs and alternative application
models. [Review] [78 refs]. Scandinavian Journal of Urology &
Nephrology Supplementum 1996;179129-138.
Herschorn S. Cardiovascular safety of PDE5 inhibitors.
[Review] [15 refs]. Can J Urol 2003;10Suppl-8.
Heyns C F. Triptorelin in the treatment of prostate cancer:
Clinical efficacy and tolerability. Am J Cancer 2005;4(3):169­
183.
Hijazi R A, Cunningham G R. Andropause: is androgen
replacement therapy indicated for the aging male?. [Review]
[123 refs]. Annu Rev Med 2005;56117-137.
Hijazi R A, Betancourt-Albrecht M, Cunningham G R. Gonadal
and erectile dysfunction in diabetics. Med Clin North Am
2004;88(4):933-945.
Hirooka Y, Shimokawa H. Therapeutic potential of rho-kinase
inhibitors in cardiovascular diseases. [Review] [76 refs].
American Journal of Cardiovascular Drugs 2005;5(1):31-39.
Hood S, Kirby M. PDE-5 inhibitors - A summary. British
Journal of Diabetes & Vascular Disease 2004;4(6):383-386.
Hood S, Kirby M. Risk factor assessment of erectile
dysfunction. British Journal of Diabetes & Vascular Disease
2004;4(3):157-161.
Howes L, Martin J, Kritharides L. Diltiazem-mediated inhibition
of sildenafil metabolism may promote nitrate-induced
hypotension [1] (multiple letters). Intern Med J 2001;31(6):373­
375.
Hutter A M. Role of the Cardiologist: Clinical Aspects
of Managing Erectile Dysfunction. Clin Cardiol
2004;27(4 SUPPL.):I3-I7.
Incrocci L. Radiotherapeutic treatment of Peyronie's
disease. Expert Review of Pharmacoeconomics &
Outcomes Research 2004;4(2):235-242.
Incrocci L, Slob A K, Levendag P C. Sexual
(dys)function after radiotherapy for prostate cancer: a
review. [Review] [131 refs]. Int J Radiat Oncol Biol
Phys 2002;52(3):681-693.
Intili H. Factors in predicting initial in-office
therapeutic dosages of alprostadil for the treatment of
organic impotence. Urol Nurs 1998;18(2):111-113.
Jackson G. Phosphodiesterase type 5 inhibition in
cardiovascular disease: Experimental models and
potential clinical applications. Eur Heart J Suppl
2002;4(H):H19-H23.
Jackson G, Gillies H, Osterloh I. Past, present, and
future: a 7-year update of Viagra (sildenafil citrate).
[Review] [128 refs]. Int J Clin Pract 2005;59(6):680­
691.
Jannini E A, Lenzi A, Wagner G. New perspectives in
the pharmacotherapy of erectile dysfunction. IDrugs
2003;6(12):1165-1172.
Jeon Y H, Heo Y-S, Kim C M et al.
Phosphodiesterase: Overview of protein structures,
potential therapeutic applications and recent progress
in drug development. Cellular & Molecular Life
Sciences 2005;62(11):1198-1220.
Jiang W, Guan J, Macielag M J et al.
Pyrroloquinolone PDE5 inhibitors with improved
pharmaceutical profiles for clinical studies on erectile
dysfunction. J Med Chem 2005;48(6):2126-2133.
Jin L, Linder A E, Mills T M et al. Inhibition of the
tonic contraction in the treatment of erectile
dysfunction. Expert Opin Ther Targets 2003;7(2):265­
276.
Jnnemann K P. How effective are PDE-S inhibitors?.
Journal fur Urologie und Urogynakologie
2003;10(4):16-19.
Jockenhovel F. Testosterone therapy - What, when
and to whom?. Aging Male 2004;7(4):319-324.
Johansen K L. Treatment of hypogonadism in men
with chronic kidney disease. Advances in Chronic
Kidney Disease 2004;11(4):348-356.
Kalsi J S, Kell P D. Update on oral treatments for
male erectile dysfunction. [Review] [53 refs]. Journal
of the European Academy of Dermatology &
Venereology 2004;18(3):267-274.
D-42